IDEX Corporation — FY2023 Form 10-K Summary
Business context and reporting period
IDEX is a global applied-solutions manufacturer serving niche markets through three segments: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). This 10-K covers the fiscal year ended December 31, 2023; it is an annual report, not a standalone fourth-quarter filing.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Net sales | $3,273.9 million | $3,181.9 million | +3% |
| Organic net sales | — | -1% | |
| Operating income | $732.5 million | $751.4 million | -3% |
| Net income attributable to IDEX | $596.1 million | $586.9 million | +2% |
| Diluted EPS | $7.85 | $7.71 | +2% |
| Adjusted EBITDA | $899.6 million | $884.2 million | +2% |
| Operating cash flow | $716.7 million | $557.4 million | +29% |
| Free cash flow | $626.8 million | $489.4 million | +28% |
- Gross margin was 44.2%, down 60 basis points; net income margin was 18.2%, down 20 basis points; adjusted EBITDA margin was 27.5%, down 40 basis points.
- Operating cash flow improvement reflected lower working-capital needs, including inventory reduction. Capital expenditures were $89.9 million.
- At year-end, cash was $534.3 million, working capital was $946.0 million, and the current ratio was 2.9. Revolving credit availability was $715.6 million.
- Total borrowings were $1,333.3 million, compared with $1,477.8 million a year earlier. The company reported leverage of 1.45x and interest coverage of 18.43x for covenant purposes and was in compliance with its covenants.
Material changes versus FY2022
- Sales growth reflected a 5% contribution from acquisitions net of divestitures, partly offset by a 1% organic decline and a 1% impact from prior-year COVID-19 testing revenue that did not recur.
- FMT sales rose 7% and adjusted EBITDA rose 11%; FSDP sales rose 6% and adjusted EBITDA rose 13%. HST sales fell 2%, while adjusted EBITDA fell 13%, primarily amid customer destocking and lower demand in life sciences, analytical instrumentation, semiconductor, pharmaceutical/biopharmaceutical, and food markets.
- Price capture and productivity supported results, but lower volumes, unfavorable mix, higher employee-related costs and lower volume leverage pressured margins. SG&A increased 8%, including acquisition-related costs and amortization.
- Net income increased despite lower operating income. The 2023 results included an $84.7 million net gain on business sales, chiefly a $93.8 million gain on the Micropump sale partly offset by a $9.1 million Novotema loss. FY2022 included a $34.8 million gain on the Knight sale.
- IDEX acquired Iridian and STC for total cash consideration of approximately $311.8 million and sold Micropump and Novotema. It also recorded a $7.7 million credit-loss reserve on a collaborative-partner investment.
Outlook, risks and unusual items
- Management gave no quantified 2024 earnings or sales guidance in the provided filing text. It described demand as stable across most businesses, with early improvement signs particularly in FMT; life sciences and analytical instrumentation markets within HST were stable but not yet showing near-term recovery.
- Management expects Dispensing to contract in 2024 after the North American fleet-refresh cycle ended in 2023; anticipated growth in emerging-market Dispensing, Fire & Safety and BAND-IT is expected to partly offset this.
- Customer destocking in 2023 followed the easing of supply-chain constraints; management said orders had stabilized and backlog and lead times had returned toward more normal levels.
- Key risks include economic and industrial downturns, competitive and pricing pressure, raw-material and supply-chain disruption, interest-rate and currency movements, acquisition execution, cybersecurity, geopolitical and trade developments, climate-related requirements and events, and litigation or other contingencies.
- Asbestos-related lawsuits remain outstanding. Most resolved claims have been dismissed without payment or settled for immaterial amounts; the company says it does not currently expect a material adverse effect. Other ordinary-course legal matters are also disclosed, with management stating their ultimate disposition is not expected to have a material adverse effect.
- Goodwill and intangible assets totaled approximately $3.85 billion at year-end. Annual impairment testing found no impairment; future underperformance could nevertheless result in impairment charges. The company also recorded restructuring and asset-impairment expenses of $10.9 million in 2023.
- The independent auditor issued an unqualified opinion on the financial statements and internal controls. The internal-control assessment excluded the 2023 Iridian and STC acquisitions under the permitted acquired-business scope exclusion.
Important facts for investors to verify
- Whether HST end-market demand and customer inventory levels recover, and whether the 2024 demand commentary translates into sales and margin performance.
- How much reported earnings growth depended on divestiture gains and other adjustments; compare GAAP results with management’s non-GAAP measures and reconciliations.
- Acquisition integration, returns and purchase-accounting assumptions for Iridian and STC, including the substantial goodwill and intangible assets recorded.
- Debt maturities, floating-rate exposure and refinancing costs; $131.0 million of year-end debt was floating rate, and interest expense rose 27% in 2023.
- Potential exposure from asbestos claims, the collaborative-partner investment, and other legal or contingent matters, including the availability of insurance coverage.